CN110214022A - 免疫原性缀合物及其用途 - Google Patents
免疫原性缀合物及其用途 Download PDFInfo
- Publication number
- CN110214022A CN110214022A CN201780084552.7A CN201780084552A CN110214022A CN 110214022 A CN110214022 A CN 110214022A CN 201780084552 A CN201780084552 A CN 201780084552A CN 110214022 A CN110214022 A CN 110214022A
- Authority
- CN
- China
- Prior art keywords
- nomv
- antigen
- immunogenic conjugate
- immunogenic
- antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619946.5A GB201619946D0 (en) | 2016-11-25 | 2016-11-25 | Conjugated immunogenic derivatives and use thereof |
| GB1619946.5 | 2016-11-25 | ||
| GB1712096.5 | 2017-07-27 | ||
| GBGB1712096.5A GB201712096D0 (en) | 2017-07-27 | 2017-07-27 | Immunogenic conjugates and use thereof |
| PCT/EP2017/080145 WO2018096007A2 (en) | 2016-11-25 | 2017-11-23 | Immunogenic conjugates and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110214022A true CN110214022A (zh) | 2019-09-06 |
Family
ID=60702606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780084552.7A Pending CN110214022A (zh) | 2016-11-25 | 2017-11-23 | 免疫原性缀合物及其用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12036285B2 (enExample) |
| EP (1) | EP3544625A2 (enExample) |
| JP (2) | JP7100031B2 (enExample) |
| CN (1) | CN110214022A (enExample) |
| BE (1) | BE1025210B1 (enExample) |
| BR (1) | BR112019010227A2 (enExample) |
| CA (1) | CA3044569A1 (enExample) |
| MX (1) | MX2019006104A (enExample) |
| WO (1) | WO2018096007A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3544625A2 (en) | 2016-11-25 | 2019-10-02 | GlaxoSmithKline Biologicals S.A. | Immunogenic conjugates and use thereof |
| MX2019006105A (es) * | 2016-11-25 | 2019-08-21 | Glaxosmithkline Biologicals Sa | Conjugados de vmen-antigeno y uso de los mismos. |
| GB201712824D0 (en) | 2017-08-10 | 2017-09-27 | Glaxosmithkline Biologicals Sa | Multi-functionalized nOMV Conjugates |
| CN111358942A (zh) * | 2018-12-25 | 2020-07-03 | 国家纳米科学中心 | 一种疫苗及其制备方法 |
| JP7462864B2 (ja) * | 2019-04-19 | 2024-04-08 | 国立感染症研究所長 | メンブレンヴェシクル |
| US20220378902A1 (en) * | 2019-08-22 | 2022-12-01 | Sichuan University | Bacterial membrane vesicles, and separation and preparation system and method therefor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103687612A (zh) * | 2011-07-07 | 2014-03-26 | 由卫生福利和体育大臣代表的荷兰王国 | 无去污剂制备革兰氏阴性细菌外膜泡囊的方法 |
| WO2016083583A1 (en) * | 2014-11-28 | 2016-06-02 | Crucell Holland B.V. | Meningitis b vaccine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271147A (en) | 1980-01-10 | 1981-06-02 | Behringwerke Aktiengesellschaft | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| NZ214503A (en) | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates |
| US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| EP0467714A1 (en) | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | The class II protein of the outer membrane of neisseria meningitidis |
| CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
| EP1228217B1 (en) | 1999-04-30 | 2012-11-21 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
| IL150822A0 (en) | 2000-01-25 | 2003-02-12 | Univ Queensland | PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| WO2006124712A2 (en) | 2005-05-16 | 2006-11-23 | Merck & Co., Inc. | A method for improving the immunogenicity of plasmodium antigens |
| GB2441094B (en) | 2005-05-19 | 2010-11-03 | Edward Jenner Inst For Vaccine | Methods for treatment and prevention of infection |
| AU2013265336A1 (en) | 2012-05-22 | 2014-12-04 | Novartis Ag | Meningococcus serogroup X conjugate |
| EP2870974A1 (en) * | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
| US11066453B2 (en) * | 2015-05-18 | 2021-07-20 | Biomvis Srl | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
| US10248164B2 (en) | 2016-07-11 | 2019-04-02 | Boe Technology Group Co., Ltd. | Chip on film, flexible display apparatus having the same, and fabricating method thereof |
| EP3544625A2 (en) | 2016-11-25 | 2019-10-02 | GlaxoSmithKline Biologicals S.A. | Immunogenic conjugates and use thereof |
| MX2019006105A (es) | 2016-11-25 | 2019-08-21 | Glaxosmithkline Biologicals Sa | Conjugados de vmen-antigeno y uso de los mismos. |
-
2017
- 2017-11-23 EP EP17816487.7A patent/EP3544625A2/en active Pending
- 2017-11-23 JP JP2019527901A patent/JP7100031B2/ja active Active
- 2017-11-23 WO PCT/EP2017/080145 patent/WO2018096007A2/en not_active Ceased
- 2017-11-23 MX MX2019006104A patent/MX2019006104A/es unknown
- 2017-11-23 BE BE2017/5855A patent/BE1025210B1/fr active IP Right Grant
- 2017-11-23 BR BR112019010227A patent/BR112019010227A2/pt unknown
- 2017-11-23 US US16/462,624 patent/US12036285B2/en active Active
- 2017-11-23 CN CN201780084552.7A patent/CN110214022A/zh active Pending
- 2017-11-23 CA CA3044569A patent/CA3044569A1/en active Pending
-
2022
- 2022-06-30 JP JP2022105784A patent/JP7439174B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103687612A (zh) * | 2011-07-07 | 2014-03-26 | 由卫生福利和体育大臣代表的荷兰王国 | 无去污剂制备革兰氏阴性细菌外膜泡囊的方法 |
| WO2016083583A1 (en) * | 2014-11-28 | 2016-06-02 | Crucell Holland B.V. | Meningitis b vaccine |
Non-Patent Citations (1)
| Title |
|---|
| LUCILA O. FUKASAWA等: "Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate", 《VACCINE》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BE1025210A1 (fr) | 2018-12-05 |
| WO2018096007A3 (en) | 2018-11-15 |
| CA3044569A1 (en) | 2018-05-31 |
| EP3544625A2 (en) | 2019-10-02 |
| JP7100031B2 (ja) | 2022-07-12 |
| JP2019535775A (ja) | 2019-12-12 |
| BR112019010227A2 (pt) | 2019-10-08 |
| WO2018096007A2 (en) | 2018-05-31 |
| JP2022130637A (ja) | 2022-09-06 |
| JP7439174B2 (ja) | 2024-02-27 |
| MX2019006104A (es) | 2019-08-21 |
| US20230137821A1 (en) | 2023-05-04 |
| US12036285B2 (en) | 2024-07-16 |
| BE1025210B1 (fr) | 2018-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7439174B2 (ja) | 免疫原性コンジュゲート及びその使用 | |
| JP7074793B2 (ja) | 髄膜炎菌ワクチン | |
| EP3544637B1 (en) | Native omv-antigen conjugates and use thereof | |
| RU2634405C2 (ru) | Иммуногенная композиция | |
| JP6170932B2 (ja) | spr0096抗原およびspr2021抗原を含むキャリア分子 | |
| JP2010162038A (ja) | 髄膜炎菌タンパク質nmb1870の複数の改変体 | |
| JP2010532793A (ja) | コンジュゲートワクチン用修飾多糖 | |
| JP2012512240A (ja) | ヘモグロビン受容体を含む髄膜炎菌ワクチン | |
| KR101266552B1 (ko) | 그룹 y 수막염균에 대한 백신 및 그의 수막염균성 조합 | |
| US20240293524A1 (en) | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | |
| CN116898960A (zh) | 细菌多糖蛋白缀合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190906 |
|
| RJ01 | Rejection of invention patent application after publication |